Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel, and South Korea.

Biotechnology

Pharming Group

Pharming Group's headquarters in Leiden, Netherlands

Inés Bernal

Mireille Sanders

Anurag Relan

Dolf Kuijper

Stephen Toor

Alexander Breidenbach

Kenneth Lynard

Ewen Munro

Shawn Hayes

Mark Moore

Wesley Blankenship

Daniel Franks

Brian Hartline

Kurinji Krishnamoorthy

Hendrik van der Boog

Gregory Fuest

Caitlin Wagner

Katia Nouzille

Mike Hilton

Björn Peters

John Whalen

Andrew Baumker

Wilbert van de Veire

Ashma Riaz

Bart de Kok Ra

Nigel van Kampen

Rosemary van Giezen

Virginia Briones

Maryana Reurings-Tsiganko

Steven Baert

Deborah Jorn

Paul Sekhri

Barbara Yanni

Leonard Kruimer

Mark Pykett

Jabine van der Meijs

The Medical and Scientific Affairs team at Pharming Group focuses on ensuring the medical and scientific integrity of the company's innovative pharmaceutical products. This team is responsible for overseeing clinical research, providing medical expertise, supporting regulatory submissions, and ensuring the dissemination of accurate scientific information to healthcare professionals and stakeholders. They play a pivotal role in aligning the company's strategic goals with the latest scientific and medical advancements to enhance patient care and treatment outcomes.

Medical and Scientific Affairs

The Market Access and Business Operations team at Pharming Group is responsible for ensuring the availability and affordability of Pharming’s innovative products in various markets. They work on developing strategies for pricing, reimbursement, and access to RUCONEST®, while analyzing market data to optimize business performance. Additionally, this team collaborates with regional directors and business development specialists to expand Pharming’s reach and operational efficiency globally.

Market Access and Business Operations

The Leadership Team at Pharming Group is responsible for driving the strategic vision and operational excellence of the company. Comprising key executives such as the Chief Medical Officer, Chief Financial Officer, and Chief Commercial Officer, this team oversees the development and marketing of innovative therapeutics, ensuring compliance with regulatory standards while addressing the needs of patients with rare diseases. They collaborate to align objectives, optimize resources, and foster a culture of ethical practices within the organization.

Leadership Team

The Compliance and Regulatory Affairs team at Pharming Group ensures that all company activities adhere to regulatory requirements and ethical standards. They develop and implement compliance strategies, oversee regulatory submissions, manage product labeling, and maintain global standards, particularly for their lead product, RUCONEST®. This team is pivotal in navigating the complexities of pharmaceutical regulations to enable the safe and effective distribution of treatments for rare diseases.

Compliance and Regulatory Affairs

The Finance Team at Pharming Group oversees the company's financial health, ensuring robust financial planning, analysis, and reporting. They manage budgets, financial forecasting, and regulatory compliance, supporting strategic initiatives to drive growth and profitability while safeguarding financial integrity.

Finance Team

Pharming Group

Org chart

Board & advisors

Teams

Medical and Scientific Affairs

Market Access and Business Operations

Leadership Team

Compliance and Regulatory Affairs

Finance Team

Offices

Pharming Group

Org chart

Board & advisors

Teams

Medical and Scientific Affairs

Market Access and Business Operations

Leadership Team

Compliance and Regulatory Affairs

Finance Team

Offices

Related companies